According to Zacks, “Juno suffered a huge setback in Jul 2016 with the FDA placing a clinical hold on a phase II study on JCAR015 in patients with relapsed or refractory B cell acute lymphoblastic leukemia. While the hold was lifted a week later and the study has resumed under a revised protocol, timelines have been pushed out with Juno now guiding towards FDA approval of JCAR015 in the first half of 2018 – the company was previously looking to gain accelerated approval in the U.S. in 2017. Moreover, estimates have moved down lately ahead of the company’s Q3 earnings release. The company also has a negative record of earnings surprises in recent quarters. However, Juno continues to progress with its other pipeline candidates and continues to pursue acquisitions and licensing agreements to boost its pipeline.”
Other analysts have also recently issued research reports about the stock. FBR & Co reaffirmed a buy rating on shares of Juno Lighting in a research note on Saturday, July 9th. Leerink Swann reaffirmed a buy rating and set a $86.00 target price on shares of Juno Lighting in a research note on Thursday, July 14th. Vetr cut shares of Juno Lighting from a strong-buy rating to a buy rating and set a $38.02 target price on the stock. in a research note on Tuesday, August 16th. Maxim Group decreased their target price on shares of Juno Lighting from $80.00 to $50.00 and set a buy rating on the stock in a research note on Friday, August 5th. Finally, Barclays PLC began coverage on shares of Juno Lighting in a research note on Wednesday, July 6th. They set an equal weight rating and a $48.00 target price on the stock. Two research analysts have rated the stock with a sell rating, three have issued a hold rating, ten have assigned a buy rating and one has given a strong buy rating to the company. The company has an average rating of Buy and a consensus target price of $46.27.
Shares of Juno Lighting (NASDAQ:JUNO) traded down 1.32% during mid-day trading on Wednesday, hitting $29.26. The company’s stock had a trading volume of 738,420 shares. The company has a 50-day moving average price of $30.53 and a 200-day moving average price of $36.24. Juno Lighting has a 1-year low of $22.37 and a 1-year high of $57.82. The stock’s market cap is $2.98 billion.
Juno Lighting (NASDAQ:JUNO) last posted its earnings results on Thursday, August 4th. The biopharmaceutical company reported ($0.64) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.41) by $0.23. The business had revenue of $27.60 million for the quarter, compared to analysts’ expectations of $14.26 million. The business’s revenue was up 121.5% on a year-over-year basis. During the same quarter in the previous year, the firm posted ($0.35) earnings per share. Analysts predict that Juno Lighting will post ($2.48) EPS for the current fiscal year.
In related news, CEO Hans Edgar Bishop sold 23,042 shares of the business’s stock in a transaction on Thursday, September 8th. The shares were sold at an average price of $30.06, for a total value of $692,642.52. Following the sale, the chief executive officer now owns 2,541,151 shares of the company’s stock, valued at $76,386,999.06. The sale was disclosed in a legal filing with the SEC, which is accessible through the SEC website.
Several hedge funds have recently modified their holdings of the company. BlackRock Fund Advisors boosted its stake in shares of Juno Lighting by 14.1% in the first quarter. BlackRock Fund Advisors now owns 1,517,425 shares of the biopharmaceutical company’s stock valued at $57,799,000 after buying an additional 187,826 shares in the last quarter. Riverhead Capital Management LLC purchased a new position in Juno Lighting during the first quarter valued at about $2,845,000. BlackRock Group LTD raised its position in Juno Lighting by 15.3% in the first quarter. BlackRock Group LTD now owns 34,653 shares of the biopharmaceutical company’s stock valued at $1,320,000 after buying an additional 4,609 shares during the last quarter. Bellevue Group AG purchased a new position in Juno Lighting during the first quarter valued at about $1,409,000. Finally, DekaBank Deutsche Girozentrale raised its position in Juno Lighting by 27.1% in the second quarter. DekaBank Deutsche Girozentrale now owns 60,000 shares of the biopharmaceutical company’s stock valued at $2,374,000 after buying an additional 12,800 shares during the last quarter.
Juno Lighting Company Profile
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for Juno Lighting LLC Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Juno Lighting LLC and related companies with MarketBeat.com's FREE daily email newsletter.